Moleculin Biotech, Inc. (MBRX)

↓ Download CSV

CIK 0001659617 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Moleculin Biotech, Inc. reported revenue of $0. The company ran a net loss. It held $22.13M in total assets against $7.12M in total liabilities.

Key ratios (FY2025)

-223.6%
Return on equity
Metric (FY)2025202420232022202120202019201820172016
Revenue$0$0$0$0$0$0$0$0$0
Operating Income-$25.10M-$26.64M-$29.63M-$30.64M-$22.97M-$19.74M-$17.52M-$15.03M-$8.65M-$3.88M
Net Income-$33.56M-$26.05M-$29.77M-$29.02M-$15.89M-$17.36M-$13.21M-$11.88M-$9.80M-$3.93M
EPS (Diluted)$-28.42$-189.14$-15.07$-15.22$-0.59
Total Assets$22.13M$16.93M$38.22M$57.42M$84.09M$29.03M$25.23M$19.59M$19.48M$16.39M
Total Liabilities$7.12M$5.72M$12.14M$5.23M$5.10M$11.27M$9.66M$5.31M$2.37M$1.43M
Shareholders' Equity$15.01M$11.21M$30.93M$52.19M$78.99M$17.76M$15.57M$14.27M$17.12M$14.96M
Cash & Equivalents$8.88M$4.28M$23.55M$43.15M$70.90M$15.17M$10.73M$7.13M$7.71M$5.01M
Operating Cash Flow-$22.73M-$23.86M-$23.59M-$27.64M-$18.95M-$17.77M-$17.20M-$12.20M-$7.32M-$3.77M
Capital Expenditures$0$13.0K$124.0K$67.0K$19.0K$376.0K$52.0K$417.0K$28.0K$21.0K
Shares Outstanding3.20M135.2K2.23M1.91M28.58M11.54M7.62M28.53M21.47M12.16M